Hepatic Oncology | |
Systematic literature review of trials assessing recommended systemic treatments in hepatocellular carcinoma | |
Sarah Ronnebaum1  Dipen Patel1  Fernando Benavente2  Juan-David Rueda2  Abdalla Aly2  | |
[1] 1OPEN Health, Bethesda, MD 20814, USA;2AstraZeneca, Gaithersburg, MD 20878, USA; | |
关键词: BCLC stage; ECOG performance status; hepatocellular carcinoma; immuno-oncology agent; similarity assessment; systemic treatment; | |
DOI : 10.2217/hep-2021-0003 | |
来源: DOAJ |
【 摘 要 】
Aim: To identify and evaluate the similarity of all trials assessing recommended treatments for advanced hepatocellular carcinoma. Materials & methods: Single arm and randomized trials from any phase and published any time up to February 2021 were systematically searched. Results: From 5677 records reviewed, 50 trials were included in the review, and 24 for assessed for similarity. In the first-line (1L) setting, several trials assessing sorafenib were noted for enrolling patients with more severe disease and/or performance status than other 1L trials; trials within the second-line (2L) setting were generally similar. Median survival was <2 years in all trial arms. Conclusions: Trials assessing recommended treatments are largely similar and appropriate for quantitative comparisons of several efficacy and safety outcomes.
【 授权许可】
Unknown